A recent article published on Phillypurge.com discusses famed oncologist Dr. Mikhail Blagosklonny and the tremendous potential rewards that could result from his research with Rapamycin. Rapamycin, or Sirolimus, is already used as an anti-rejection drug for individuals who have had organ transplants. Since its discovery in 1972, scientists have been learning more and more about the drug’s antiproliferative and immunosuppressive qualities that may make it a better treatment option for a variety of different ailments. Dr. Mikhail Blagosklonny is one of those scientist that truly believe in the amazing potential of Rapamycin and is conducting extensive research into its healing properties.
When looking at the antiproliferative and immunosuppressive qualities of Rapamycin, Dr. Blagosklonny was able to see the other potential uses for it. Since it can suppress the immune system without poisoning the kidneys the same way that other medications do, it has become a leading treatment option for people who have received organs through transplant. It also has great potential in helping those individuals that suffer from the hemolytic-uremic syndrome, a condition that causes major renal failure. Because drugs of this category cause toxicity to the kidneys, organ recipients cannot be treated with typical immunosuppressants. Rapamycin is a great solution.
The antiproliferative qualities of Rapamycin represent some life-changing potentials of their own. Dr. Blagosklonny believes that since antiproliferative medications suppress the growth of malignant cells in other tissues, then it can be used to help treat individuals with cancer. If taken in the right dose, Rapamycin can also be used to boost the immune system in individuals suffering from certain types of cancers. According to Dr. Blagosklonny, the medication is also showing promising research in treating Alzheimer’s, Muscular Dystrophy, and Systemic Lupus Erythematosus.
Dr. Blagosklonny earned an M.D. in internal medicine and a PhD. in experimental medicine from the First Pavlov State Medical University of St. Peterburg. Since graduating, Dr. Blagosklonny has been an avid researcher of procedures and medications such as Rapamycin. His continued interest and education have made him an expert in the oncology field. In the article, “Mikhail Blagosklonny’s Plans for Oncology” the author discusses how Dr. Blagosklonny’s has been a driving force behind the substantial cancer research in his field. In addition to this work, he is also interested in inspiring others. To accomplish this, he serves as a professor with Roswell Park Cancer Institute, where he helps teach others about cancer.
In all of Dr. Blagosklonny’s work, he has shown that he is a kind and benevolent man. In his personal life, he is an avid philanthropist, but he does not leave that giving attitude at home. He carries that with him throughout everything he does. In fact, the focus of his work is to locate effective cancer treatments that are also economical and available to a larger portion of the population without financially decimating their financial resources. Throughout the years Dr. Blagosklonny has used his education and vocational resources to strive towards helping humanity and as he continues, he is positioned to do great things.
Seattle Genetics is a biotechnology company, headquartered in Bothell, Washington, that has a primary focus on commercializing and developing antibody based therapies to treat cancer. They are known as an industry leader in developing antibody-drug conjugates, known as ADC’s. These drugs are powerful in the treatment of cancer as they can deliver cell-kiling agents directly to cancer cells. ADC’s are specifically designed to spare cells that are not cancerous, and thus, reduces many of the toxic effects of traditional cancer treatments. This is also in addition to the unique ability to potentially enhance anti-tumor activity. Seattle Genetics‘ success in the production of these drugs makes them a key alley in the fight against cancer.
The company was founded in 1997 and, to date, currently employs more than 650 individuals across the United States. In 2001, the company completed a public offering and began to be traded on the Nasdaq Stock Market under the symbol SGEN. Seattle Genetics’ CEO, Clay Siegall, is a scientist with extensive training that emphasizes different cancer treatments and drug therapies. Under his guidance, the company has entered into multiple strategic licenses for its ADC’s. A few of these licenses include,: Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer. These licenses, to date, have generated over $300 million. Prior to co-founding and managing Seattle Genetics, Dr. Clay Siegall worked for the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute for several years. Dr. Siegall also contributes his knowledge to several other different agencies, including serving on the board of directors for: Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and Washington Roundtable.